Altimmune
ALT
37 hedge funds and large institutions have $46.4M invested in Altimmune in 2014 Q3 according to their latest regulatory filings, with 6 funds opening new positions, 8 increasing their positions, 11 reducing their positions, and 5 closing their positions.
200% more funds holding in top 10
Funds holding in top 10: 1 → 3 (+2)
133% more call options, than puts
Call options by funds: $147K | Put options by funds: $63K
64% more capital invested
Capital invested by funds: $28.3M → $46.4M (+$18.1M)
20% more first-time investments, than exits
New positions opened: 6 | Existing positions closed: 5
3% more funds holding
Funds holding: 36 → 37 (+1)
27% less repeat investments, than reductions
Existing positions increased: 8 | Existing positions reduced: 11
Top Buyers
Top Sellers
| 1 |
Morgan Stanley
New York
|
-$136K |
| 2 |
Group One Trading
Chicago,
Illinois
|
-$120K |
| 3 |
CCA
Catalyst Capital Advisors
Huntington,
New York
|
-$92K |
| 4 |
PCM
Potomac Capital Management
New York
|
-$82.6K |
| 5 |
U
UBS
Zurich,
Switzerland
|
-$47.6K |
ALT Hedge Fund Activity: Q3 2014 in Review
37 of the 3,446 institutional investors tracked by Wall St. Rank reported a position in Altimmune (ALT) for Q3 2014, worth a combined $46.4M — up 64% from $28.3M a quarter earlier.
Buyers outnumbered sellers: 6 funds opened new ALT positions and 5 closed out — a net gain of 1 holder — while 8 added to existing stakes and 11 trimmed.
The largest buyer was Prescott Group Capital Management, adding an estimated $4.77M. The largest seller was Morgan Stanley, cutting an estimated $136K.
- 37 institutional investors held Altimmune (ALT) as of Q3 2014, up from 36 in Q2 2014.
- Funds reported $46.4M of Altimmune stock for Q3 2014, up 64% quarter-over-quarter.
- 6 funds opened new Altimmune positions in Q3 2014 and 5 closed out, a net change of +1 holder.
- The largest Altimmune buyer in Q3 2014 was Prescott Group Capital Management, an estimated $4.77M added.
- The largest Altimmune seller in Q3 2014 was Morgan Stanley, an estimated $136K sold.
Based on aggregated 13F filings for Q3 2014.